Holdings

Symbol Grade Price % Change Allocation
CORT B 0.95 3.39
BMY B 0.22 2.69
LBPH A -0.01 2.67
ITCI B -0.41 2.63
JAZZ B 2.91 2.63
VTRS A 0.65 2.48
AXSM B 0.42 2.38
EWTX C 1.06 2.38
CTLT D 1.29 2.22
ELAN D -1.00 2.18
PRGO C -0.41 2.13
RPRX D 1.43 2.10
JNJ D 1.06 2.06
ZTS D 0.75 2.04
PFE F -0.24 2.00
LLY F -1.23 1.98
MRK F 1.23 1.90
TARS C 0.86 1.86
ARVN F 6.65 1.73
OGN F 0.81 1.70
SAVA D 7.22 1.68
PBH A 0.27 1.60
SUPN B -1.26 1.46
AMPH F 0.20 1.39
PCRX C 2.47 1.27
LGND C 5.03 1.20
ANIP D 1.21 1.04
OCUL C -2.51 1.00
COLL F 1.37 1.00
AMRX C -0.77 0.89
HROW D 3.86 0.88
HRMY F 0.09 0.84
WVE C 4.17 0.80
MNMD C -4.50 0.78
INVA D 0.00 0.67
EYPT D -5.19 0.65
LQDA F 0.89 0.61
FULC F 2.17 0.60
PLRX D 2.71 0.60
ELVN C -0.39 0.45
NUVB C 2.71 0.40
EOLS F 2.26 0.36
PHAT F 8.13 0.33
XERS C 1.31 0.31

Recent News for Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF & its Holdings

Date Stock Title
Nov 21 PFE Major companies that are also popular short-selling stocks
Nov 21 PFE The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair
Nov 21 VTRS Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)
Nov 21 PFE Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Nov 21 PFE 2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Nov 21 HRMY HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
Nov 21 JAZZ Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
Nov 21 HROW Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
Nov 21 JAZZ Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
Nov 21 PFE EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
Nov 21 PFE 2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 21 JAZZ Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
Nov 20 ZTS Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript)
Nov 20 PFE CDC warns of an imminent spike in COVID, flu cases
Nov 20 MRK Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
Nov 20 JNJ Update: Market Chatter: Johnson & Johnson, Merck Cut Jobs in China
Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
Exchange Traded Funds
Back to the Main PILL Page...